PFNLive
- Elan Completes Sale of Tysabri Stake to Biogen
- Resurgent Pfizer Partners with Bind on New Nanotech Drug Effort
- Wall Street Rises with Health Insurers, S&P Nears Record
- Clavis Preps Endgame After Final PhIII Cancer Drug Failure
- Thermo Fisher Emerges as Frontrunner for Life Tech
- Wall Street up on Health Insurers, S&P Near Intraday Record
- Obagi Medical Gets Higher Offer from Merz Pharma
- AmerisourceBergen Agrees to Sell Packaging Business
- Wall Street Edges up Ahead of Data
- PolyMedix Defaults and Hands Over a PhII Antibiotic to Bankruptcy Court
- Humana Rises as U.S. Reverses Medicare Rate Cut Decision
- AstraZeneca Suffers Fresh Drug Patent Setback in U.S.
- Stocks Dip After Manufacturing Growth Slows
- Daiichi Sankyo Ditches Cancer Drug Program from ArQule
- BioCryst's Shares Spike on Hope that Flu Drug can Rise from the Grave
- Novartis Cancer-Drug Patent Denied by India Supreme Court
- Wall Street Set for Flat Open After S&P's Closing High
- Biogen Prices Tecfidera Below Oral MS Rival Gilenya
- J&J Wins First FDA Approval for New Class of Diabetes Drug
- Alexion Gets FDA Warning but Doesn't Expect Soliris Disruption
